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Background: The role and mechanism of action of MIF in bronchopulmonary dysplasia (BPD) are not known. We
hypothesized that increased MIF signaling would ameliorate the pulmonary phenotype of BPD in the mouse lung.
Methods: We studied newborn wild type (WT), MIF knockout (MIFKO), and lung MIF transgenic (MIFTG) mice in
room air and a BPD model, and examined the effects of administering a small molecule MIF agonist and
antagonist. Lung morphometry was performed and mRNA and protein expression of vascular mediators were
analyzed.
Results: The pulmonary phenotype of MIFKO and MIFTG mice lungs in room air (RA) and BPD model were
comparable to the WT-BPD mice at postnatal (PN) day 14. Vascular endothelial growth factor (VEGF)-A, -R1 and
Angiopoietin (Ang)1 mRNA were decreased, and Ang2 increased in the WT-BPD, MIFKO-RA, MIFKO-BPD, MIFTG-RA
and MIFTG-BPD mice lungs, compared to appropriate controls. The protein expression of Ang1 in the MIFKO-RA
was similar to WT-RA, but decreased in MIFTG-RA, and decreased in all the BPD groups. Ang2 was increased in
MIFKO-RA, MIFTG-RA and in all 3 BPD groups. Tie2 was increased in WT-BPD compared to WT-RA, but decreased in
MIFKO- and MIFTG- RA and BPD groups. VEGFR1 was uniformly decreased in MIFKO-RA, MIFTG-RA and in all 3 BPD
groups. VEGF-A had a similar expression across all RA and BPD groups. There was partial recovery of the pulmonary
phenotype in the WT-BPD model treated with the MIF agonist, and in the MIFTG mice treated with the MIF
antagonist.
Conclusions: These data point to the careful regulatory balance exerted by MIF in the developing lung and
response to hyperoxia and support the potential therapeutic value of small molecule MIF modulation in BPD.
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The pathogenesis of bronchopulmonary dysplasia (BPD),
which is the most common chronic lung disease of in-
fancy, is multifactorial, with important contributions from
both genetic and environmental factors [1]. The pulmon-
ary phenotype of BPD is that of impaired alveolarization,
as exemplified by large, simplified alveoli and dysregulated
vascularization [1]. The anatomic foundation of BPD is* Correspondence: vineet.bhandari@yale.edu
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reproduction in any medium, provided the orthat of lung immaturity. We previously reported that fetal
murine lungs deficient in the growth regulatory and in-
flammatory cytokine, macrophage migration inhibitory
factor (MIF), show impaired lung maturation [2]. In
addition, human infants who have adverse pulmonary out-
come or develop BPD have been reported to have lower
tracheal aspirate levels of MIF [2,3] and are more likely to
have a low expression MIF allele [4]. The specific role and
mechanism of action of MIF in BPD are not known.
Exposure of the developing lung to hyperoxia is a critical
factor in the occurrence of BPD [1,5], thus highlighting the
need for understanding the role of hyperoxia among the
environmental factors contributing to “new” BPD [1,6,7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hyperoxia-induced lung injury in the context of the role of
host mediators such as MIF would be helpful in formulat-
ing potential therapeutic strategies with the goal of ameli-
orating BPD [7,8].
We hypothesized that increased MIF signaling would
ameliorate the pulmonary phenotype of BPD in the
mouse lung. To address this hypothesis, we studied new-
born (NB) mice genetically deficient in MIF (MIF knock
out: MIFKO). We also examined the phenotypic re-
sponse of novel lung-targeted MIF overexpressing trans-
genic (MIFTG) mice. These genetically defined mouse
strains were further subjected to a mouse model of BPD,
sacrificed at post natal (PN) day 14. In addition, we stud-
ied the effects of administering novel, small molecule
modulators of MIF signal transduction [9,10].
Our goal was to study alterations in pulmonary pheno-
type and the expression of vascular mediators in the var-
ied mouse models. Specifically, we evaluated lung
morphometry and the expression of vascular endothelial
growth factor (VEGF), its receptors (R1-3), angiopoietin
(Ang), and its receptor (Tie2) in the lung.
Methods
Animals
MIFKO mice were backcrossed for this study into the
C57BL/6 genetic background (generation N10) [2]. We
have recently reported the generation and characterization
of the pulmonary phenotype of the lung-targeted MIF
transgenic (MIFTG) mouse [11]. Briefly, we targeted the
lung by using rat Clara Cell 10kD protein (CC10), which
is a Type II epithelial-cell and conducting airway-cell spe-
cific promoter in the developing lung [12]. We developed
the TG mice on the C57BL/6 background, and confirmed
the constitutive MIF mRNA and protein overexpression
in lung tissue and bronchoalveolar lavage (BAL) fluid.
All animal work was approved by the Institutional
Animal Care and Use Committee at the Yale University
School of Medicine.
Newborn mouse BPD model
For the NB animals, exposure to hyperoxia (along with
their mothers) was performed by placing mice in cages in
an airtight Plexiglass chamber (55 × 40 × 50 cm), as
described previously [13,14]. For the NB mouse model of
BPD, exposure to 100% oxygen was initiated on PN1 and
continued until PN4 (saccular stage of mouse lung devel-
opment) and allowed to recover in room air (RA) for the
next 10 days (alveolar stage of mouse lung development).
Two lactating dams were used and alternated in hyperoxia
and RA every 24 h, during the hyperoxia phase (PN1-4) of
the experimental model. The litter size was limited to 10–
12 pups per dam to control for the effects of litter size on
nutrition and growth. Mice were sacrificed on PN14. Usingthis experimental model, NB WT mouse lungs at PN14
have the phenotype mimicking human BPD, as has been
reported previously by us [15] and other investigators [16].
Throughout the experiment, mice were given free access
to food and water, and oxygen levels were continually
monitored. The inside of the chamber was maintained at
atmospheric pressure and mice were exposed to a 12 hr
light–dark cycle. We opened the oxygen chamber once a
day (from PN1-4; they were in RA from PN5-14) to
change the mothers and inject the mouse pups with
the MIF agonist and antagonist molecules [9]. The
MIF agonist, 4-(4-(pyridin-3-yl)-1H-1,2,3-triazol-1-yl)
phenol, designated MIF020 (compound 5a) [9] and the MIF
antagonist, 3-(3-hydroxybenzyl)-5-methylbenzooxazol-2-one,
designated MIF098 (compound 5) [10] were dissolved in
10% DMSO (Vehicle 1) at a concentration of 0.04 mg/μl,
and administered intra-dermally from PN1-4 and intra-
peritoneally from PN5-14, at a dose of 0.4 mg/g/day.Analysis of mRNA
RNA was isolated from frozen lungs using TRIzol Reagent
(Invitrogen Corporation, Carlsbad, CA) and treated by
DNase. RNA samples were then purified by RNeasy kit
(Qiagen Sciences, Maryland, USA) according to the
manufacturer’s instructions. RNA samples were subjected
to semi-quantitative RT-PCR.




MIF-F, 5’- ATGCCTATGTTCATCGTGA -3’
MIF-R, 5’-TCAAGCGAAGGTGGAACCGTT −3
VEGF-A-F, 5’- GACCCTGGCTTTACTGCTGTA -3’
VEGF-A-R, 5’- GTGAGGTTTGATCCGCATGAT -3’
VEGF-C-F, 5’- AACGTGTCCAAGAAATCAGCC -3’
VEGF-C-R, 5’- AGTCCTCTCCCGCAGTAATCC -3’
VEGF-R1-F, 5- CACCACAATCACTCCAAAGAAA -3’
VEGF-R1-R, 5- CACCAATGTGCTAACCGTCTTA -3’
VEGF-R2-F, 5- ATTGTAAACCGGGATGTGAAAC -3’
VEGF-R2-R, 5- TACTTCACAGGGATTCGGACTT -3’
VEGF-R3-F, 5- GCTGTTGGTTGGAGAGAAGC -3’
VEGF-R3-R, 5- TGCTGGAGAGTTCTGTGTGG -3’
Ang1-F, 5’- AGGCTTGGTTTCTCGTCAGA -3’
Ang1-R, 5’- TCTGCACAGTCTCGAAATGG -3’
Ang2-F, 5’- GAACCAGACAGCAGCACAAA -3’
Ang2-R, 5’- AGTTGGGGAAGGTCAGTGTG -3’
Tie2-F, 5’- GGACAGTGCTCCAACCAAAT -3’
Tie2-R, 5’- TTGGCAGGAGACTGAGACCT -3’
mRNA band densities were measured by densitometry
using NIH image J and expressed in Arbitrary Densito-
metric Units (ADU), as previously described [12].
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Lung tissues obtained from the NB mice from the RA
and BPD model experiments at PN14 were subjected to
a standard protocol for lung inflation (25 cm) and fixed
overnight in 10% buffered formalin [17]. After washing
in fresh PBS, fixed tissues were dehydrated, cleared, and
embedded in paraffin by routine methods. Sections
(5 μm) were collected on Superfrost Plus positively
charged microscope slides (Fisher Scientific Co., Houston,
Texas, USA), deparaffinized, and stained with hematoxylin
& eosin, as described previously [14].
Lung morphometry
Alveolar size was estimated from the mean chord length
of the airspace, as described previously [14]. Chord
length increases with alveolar enlargement.
Bronchoalveolar lavage (BAL) fluid total cell counts
BAL fluid was obtained and total cell counts enumerated,
as previously reported [18].
Western blotting
We detected MIF, Ang1, Ang2, Tie2, VEGF-A, and
VEGFR1 protein with β-actin as control from lung lysates
using Western analysis, as described previously [14,19].
Anti-MIF specific and Tie2 antibodies were purchased
from Abcam (Cambridge, MA). Ang1 and Ang2 antibodies
were purchased from Millipore (Billerica, MA). VEGF-A
and β-actin antibodies were purchased from Santa Cruz
Biotechnology, Santa Cruz, CA. VEGFR1 antibody was
obtained from Sigma-Aldrich, St. Louis, MO.Figure 1 Effect of hyperoxia on MIF expression in NB WT mice lungs
expression in lungs of NB mice exposed to hyperoxia (as described in “Met
4 PN days. The figure is representative of n=3-4 mice per group. (B) Semi-q
model and control mice exposed to RA, at PN14. (C) Western blot of MIF p
exposed to RA, at PN14. The mouse BPD model was generated (described
exposed to RA for 14 days. The figure is representative of n=3-4 mice per g
factor; PN: post natal; RA: room air; BPD: bronchopulmonary dysplasia mouStatistical analyses
Values are expressed as mean ± SEM. Groups were
compared with the Student's two-tailed unpaired t test,
using GraphPad Prism 3.0 (GraphPad Software, Inc., San
Diego, CA), as appropriate. A P<0.05 was considered
statistically significant.Results
Effect of hyperoxia on MIF expression in NB WT mice
lungs and the mouse BPD model
In independent experiments, using the NB mouse, we
noted significantly decreased expression of MIF protein
(Figure 1A) in WT mice lungs exposed to 100% O2 at
PN4. At PN14, using the NB BPD model, we noted some
recovery of MIF mRNA (Figure 1B) and protein
(Figure 1C) expression, but MIF expression was still
markedly decreased compared to RA controls.
Taken together these data suggest that exposure to
hyperoxia during the critical stage of saccular phase of
lung development (PN1-4) leads to decreased MIF levels
in the lung, which persists even after recovery in RA for
the next 10 days (PN5-14).Role of MIF in the mouse BPD model: impact on
pulmonary phenotype and BAL total cell counts
We [15] and others [16,20] have reported on a mouse
model of BPD created by exposure of WT mice to
hyperoxia during the saccular stage of lung development
(PN1-4), followed by RA recovery for 10 days. This model
has clinical significance to human BPD in pulmonaryand the mouse BPD model. (A) Western blot of MIF protein
hods” section) from PN1 to PN4. Control lungs were exposed to RA for
uantitative RT-PCR of MIF mRNA expression in lungs of NB BPD mouse
rotein expression in lungs of NB BPD mouse model and control mice
in “Methods” section), as previously reported [15]. Control mice were
roup. β: beta; HYP: hyperoxia; MIF: macrophage migration inhibitory
se model.
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[5,21].
MIFKO and MIFTG mice in RA had lungs with
altered alveolar architecture characterized by alveolar
simplification at PN14 when compared to WT mice in
RA (Figure 2A). As expected, WT mice subjected to
hyperoxia from PN1-4, followed by recovery for next 10 -
days showed alveolar simplification characteristic of BPD
(Figure 2A). However, the exposure of MIFKO and
MIFTG mouse pups to hyperoxia from PN1-4 followed
by recovery for next 10 days did not further worsen the
pulmonary phenotype than that observed in RA, and
was confirmed by lung morphometry (Figure 2B). The
total BAL fluid cell counts were increased in the WT
and MIFKO mice in the BPD model at PN14 when
compared to respective controls (Figure 2C). Interest-
ingly, the MIFTG mice in RA and the BPD model had
similarly high values of the total BAL fluid cell counts
(Figure 2C).Figure 2 Role of MIF in the mouse BPD model: impact on pulmonary
control mice were exposed to 100% O2 for PN1-4, with recovery in RA from
histology (H&E stain) of NB MIF KO, MIF TG and WT control mice exposed t
minimum of 7 animals in each group. Alveolar size, as measured by chord
represents the mean ± SEM of a minimum of 7 animals. BAL total cell coun
or BPD model (2C). Each bar represents the mean ± SEM of a minimum of
inhibitory factor knock out; MIF TG +: macrophage migration inhibitory fac
model: bronchopulmonary dysplasia mouse model. *P<0.05; ##P<0.0001.These data indicate that both, a lack or an excess of MIF
in the developing lung leads to significant alterations in
pulmonary architecture. This result highlights the likely
requirement for “just the right amount” of MIF for normal
lung development (“Goldilocks effect”). In addition, it
suggests that excess MIF concentrations in RA in MIFTG
mice appear to have an equivalent impact on pulmonary
inflammation (based on total BAL cell counts) and pheno-
type as in the BPD model. MIF’s impact in the developing
lung is thus similar to the effect of hyperoxia, with the lat-
ter having presumptive effects on a potential number of
molecular mediators.
Role of MIF in the mouse BPD model: impact on mRNA
and protein expression of vascular factors and their
receptors
VEGF-A mRNA expression was uniformly decreased in
the WT-BPD, MIF KO-RA, MIF KO-BPD, MIF TG-RA
and MIF TG-BPD mouse lungs when compared to WT-phenotype and BAL total cell counts. NB MIF KO, MIF TG and WT
PN5-14 (BPD model). Representative photomicrographs of lung
o RA or BPD model at PN14 (2A). The figures are illustrative of a
length, confirmed features noted on lung histology (2B). Each bar
t of NB MIF KO, MIF TG and WT control mice exposed to RA at PN14
5 animals. MIF +/+: wild type; MIF −/−: macrophage migration
tor (over-expressing) transgenic; BAL: bronchoalveolar lavage; BPD
Figure 3 Role of MIF in the mouse BPD model: impact on mRNA expression of vascular factors and their receptors. NB MIF KO, MIF TG
and WT control mice were exposed to 100% O2 for PN1-4, with recovery in RA from PN5-14 (BPD model). The mice were sacrificed at PN14. The
ratios of mRNA of VEGF -A, -C and their receptors -R1 and -R3 (3A and 3B) as well as Ang1 and Ang2 and their receptor Tie2 (3C) with β-actin
were quantified by densitometry. The noted values represent assessments in a minimum of 7 animals in each group. The figure is representative
of n=3-4 mice per group. MIF +/+: wild type; MIF −/−: macrophage migration inhibitory factor knock out; MIF TG +: macrophage migration
inhibitory factor (over-expressing) transgenic; BPD: bronchopulmonary dysplasia mouse model. VEGF: vascular endothelial growth factor;
R: receptor; Ang: angiopoietin; β-actin: beta-actin. ##P<0.0001, #P≤0.01, *P<0.05.
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expression was significantly decreased in the MIF KO-
BPD lung compared to the WT-BPD control lungs
(Figure 3A), which is consistent with the association of
decreased VEGF in animal models and humans with BPD
[14].
VEGF-R1 mRNA expression was uniformly decreased
in the WT-BPD, MIF KO-RA, MIF KO-BPD, MIF TG-
RA and MIF TG-BPD mouse lungs when compared to
WT-RA control mouse lungs (Figure 3B). No differences
were noted in VEGF-R2 mRNA expression among the
groups (data not shown). With respect to Ang, the ex-
pression of Ang1 mRNA expression was significantly
decreased in MIF KO-RA and MIF TG-RA mouse lungs
when compared with WT-RA mouse lungs (Figure 3C).
A similar decrease was noted in the MIF KO-BPD and
MIF TG-BPD mice when compared to its control, WT-
BPD (Figure 3C). In contrast, Ang2 mRNA expressionwas significantly increased in the MIF TG-RA and MIF
TG-BPD lungs when compared to WT-RA and MIF
KO-RA and WT-BPD and MIF KO-BPD lungs, respect-
ively (Figure 3C).
The receptor for Ang 1 and 2 is Tie2. The expression
of Tie2 was significantly decreased in the WT-BPD, MIF
KO-RA, and MIF KO-BPD lungs when compared to
WT-RA lungs (Figure 3C). By contrast, the expression of
Tie2 was increased in the MIF TG-BPD lungs when
compared with the MIF KO-BPD lungs (Figure 3C).
We confirmed the RNA data at the protein level
(Figures 4A-C). The protein expression of Ang1 in the
MIFKO-RA was similar to WT-RA, but decreased in
MIFTG-RA, and decreased in all the BPD groups. Ang2
was increased in MIFKO-RA, MIFTG-RA and in all 3
BPD groups. Tie2 was increased in WT-BPD compared
to WT-RA, but decreased in MIFKO- and MIFTG- RA
and BPD groups. VEGFR1 was uniformly decreased in
Figure 4 Role of MIF in the mouse BPD model: impact on protein expression of vascular factors and their receptors. NB MIF KO, MIF TG
and WT control mice were exposed to 100% O2 for PN1-4, with recovery in RA from PN5-14 (BPD model). The mice were sacrificed at PN14.
Ang1, Ang2, Tie2, VEGF-A, and VEGFR1 proteins, with β-actin as controls, were detected by western blotting (4A). The relative density of VEGF -A
and it’s receptor -R1 as well as Ang1 and Ang2 and their receptor Tie2 (4B and 4C) were quantified by densitometry. The figure is representative
of n=3 mice per group. MIF +/+: wild type; MIF −/−: macrophage migration inhibitory factor knock out; MIF TG +: macrophage migration
inhibitory factor (over-expressing) transgenic; BPD: bronchopulmonary dysplasia mouse model. VEGF: vascular endothelial growth factor; R:
receptor; Ang: angiopoietin; β-actin: beta-actin. ##P<0.001, #P≤0.01, *P<0.05.
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VEGF-A had a similar expression across all RA and BPD
groups. Taken together, these data would suggest an im-
portant role of the Ang-Tie2 axis in relation to MIF sig-
naling in the mouse BPD model.Role of MIF agonist in the mouse BPD model: impact on
pulmonary phenotype and BAL total cell counts
Small molecule modulators of MIF signaling recently
have been described that either enhance or inhibit MIF
interaction with its receptor, CD74 [9,10]. Since lack of
Figure 5 Impact of MIF agonism in the mouse BPD model as reflected by pulmonary phenotype and BAL total cell counts. NB WT
control mice were exposed to 100% O2 for PN1-4, with recovery in RA from PN5-14 (BPD model). From PN1-14, some mice were treated with
vehicle 1 or the MIF agonist, MIF020 (0.04 mg/g/d; dissolved in vehicle 1). Representative photomicrographs of lung histology (H&E stain) of NB
WT mice exposed to RA or hyperoxia (BPD model), or given treatment as noted above, at PN14 (5A). The figures are illustrative of a minimum of
3 animals in each group. Alveolar size, as measured by chord length, confirmed features noted on lung histology (5B). Each bar represents the
mean ± SEM of a minimum of three animals. BAL total cell count of NB WT mice exposed to RA or BPD model, or given treatment as noted
above, at PN14 (5C). Each bar represents the mean ± SEM of a minimum of three animals. MIF +/+: wild type; MIF −/−: macrophage migration
inhibitory factor knock out; BPD Model: bronchopulmonary dysplasia mouse model; Vehicle 1: 10% DMSO; MIF Agonist: MIF020; BAL:
bronchoalveolar lavage. ##P<0.0001, #P≤0.01, *P<0.05.
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ment of BPD, we tested whether the administration of
the MIF agonist, MIF020, would ameliorate the patho-
logic effects of the BPD pulmonary phenotype. As
shown in Figure 5A and B, MIF020 improved alveolar
architecture, although the vehicle alone (10% DMSO in
PBS) was associated with a modest increase in chord
lengths. Enumeration of cells in BAL fluid also revealed
increased values in all 3 BPD groups when compared to
their respective RA controls (Figure 5C).
Role of MIF antagonist in the mouse MIFTG-BPD model:
impact on pulmonary phenotype and BAL total cell counts
Since an excess of MIF also predisposes to BPD, we tested
the effect of the MIF antagonist, MIF098 [10], in the
MIFTG-RA and MIFTG-BPD models. The administrationof MIF098 significantly improved alveolar architecture in
the MIFTG-mice in the BPD model (Figure 6A and B).
The observed improvement in alveolar architecture was
partial at the dose tested however, and did not reach WT-
RA values (Figure 6A and B). Total cell counts in BAL
fluid revealed increased numbers in the WT-BPD group,
compared to WT-RA control (Figure 6C), with no
differences in total BAL cell counts in any of the other
groups. Interestingly, BAL fluid cell counts were very simi-
lar in the MIFTG-BPD group treated with the MIF antag-
onist when compared to the similarly treated MIFTG-RA
group (Figure 6C), and this observation parallels the simi-
lar chord length values recorded in these two experimen-
tal groups (Figure 6A and B).
These data suggest that MIF antagonism may influ-
ence alveolar architecture in the MIFTG-BPD lung by
Figure 6 Impact of pharmacologic MIF antagonism in the mouse MIF TG BPD model as reflected by pulmonary phenotype and BAL
total cell counts. NB MIF TG or WT mice were exposed to 100% O2 for PN1-4, with recovery in RA from PN5-14 (BPD model). From PN1-14,
some mice were treated with vehicle 1 or the MIF antagonist, MIF098 (0.04 mg/g/d; dissolved in vehicle 1). Representative photomicrographs of
lung histology (H&E stain) of NB MIF TG or WT mice exposed to RA or hyperoxia (BPD model), or given treatment as noted above, at PN14 (6A).
The figures are illustrative of a minimum of 3 animals in each group. Alveolar size, as measured by chord length, confirmed features noted on
lung histology (6B). Each bar represents the mean ± SEM of a minimum of three animals. BAL total cell count of NB MIF TG or WT mice exposed
to RA or BPD model, or given treatment as noted above, at PN14 (6C). Each bar represents the mean ± SEM of a minimum of three animals. MIF
TG +: macrophage migration inhibitory factor (over-expressing) transgenic; BPD Model: bronchopulmonary dysplasia mouse model; Vehicle
1: 10% DMSO; MIF Antagonist: MIF098; BAL: bronchoalveolar lavage. #P≤0.01, *P<0.05.
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tial improvement in alveolar architecture in the MIFTG-
BPD model treated with MIF098 is probably due to the
fact that the action of excess MIF occurs unabated after
embryonic (E) day 14 (when the lung MIFTG is
activated within the Type II alveolar epithelium) and the
antagonist was administered only after PN1.
Discussion
The present studies were undertaken to better define
MIF’s role in the development of BPD, and employed
both genetic loss- and gain-of-function strategies with
MIFKO and MIFTG mice, respectively. We used the
hyperoxia-induced BPD model and tested the efficacy of
a recently developed, small molecule MIF agonist and
antagonist.
Hyperoxia is a significant cause of lung injury and
contributes to the pathogenesis of BPD [7] and our ini-
tial evaluation revealed a significant decrease in MIFexpression at PN4 after hyperoxia exposure. In our
mouse BPD model, at PN14, MIF expression was also
markedly decreased compared to controls. These data
are in accord with our previously reported significantly
decreased MIF concentrations in tracheal aspirates in
the first 48 h of NB human subjects (in the saccular
stage of lung development) exposed to hyperoxia who
go on to develop BPD at 36 weeks corrected
postmenstrual age, compared to those who do not de-
velop BPD [2]. Support for decreased levels of MIF being
involved in the pathogenesis of BPD has also been
demonstrated in tracheal aspirate fluid from extremely
premature infants exposed to systemic fetal inflamma-
tion early in life [3]. Antenatal exposure to inflammation
has been associated as one of the factors playing in the
development of BPD [5,22,23].
In addition to impaired alveolarization, there is
dysregulated vascularization in BPD [5]. The mouse
model of BPD described previously by us [15] and others
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lar to human BPD [25]. MIFKO and MIFTG mice in RA
at PN14 showed altered alveolar architecture that did
not worsen further upon hyperoxia exposure. This
reiterates two points: first, an optimal amount of MIF is
required for normal lung development, and second, the
severity of impaired alveolarization with lack or excess
of MIF is equivalent to that caused by hyperoxia in the
WT developing lung in the saccular stage, with no addi-
tive effect of hyperoxia in the MIFKO and MIFTG
mouse lung phenotype. We suggest that the need for
“just the right amount” of MIF is important, and this
(the “Goldilocks effect”) has been recognized by other
investigators in relation to lung [26] and inner ear [27]
development. This specific stage of lung development
(i.e. saccular) being crucial for development of the
murine BPD phenotype in relation to cytokine over-
expression in other TG models has been previously
noted by us [15] and others [28].
A dysregulation in vasculogenesis is another critical
component of BPD. Hence, an evaluation of the develop-
mental expression of vascular mediators in these models
has the potential to provide mechanistic insight. Ang1
protein expression was decreased in the WT-BPD,
MIFKO-BPD and MIFTG-BPD, while Ang2 was increased
in all 3 BPD groups (Figure 4). Our data would suggest an
important role of the Ang2-Ang1 ratio in the context of
MIF signaling in the BPD model. This has potential trans-
lational significance given the reported association of
increased Ang2 [19,29] and decreased Ang1 [30] with
human BPD.
The administration of a pharmacologic MIF agonist
that enhances MIF binding to its receptor was found to
be partially protective in the WT-BPD model. We did
note some adverse impact on alveolarization of the ve-
hicle used (10% DMSO) to dissolve the agonist. We used
the dose noted in studies conducted with adult mice
[31], which probably led to the adverse impact on
alveolarization. A lower concentration of DMSO would
be preferred for future studies, as DMSO has been used
safely in hyperoxia-exposed neonatal mice [32,33]. Con-
versely, the administration of a small molecule MIF an-
tagonist that blocks MIF binding with its receptor also
was protective in the MIFTG-RA and MIFTG-BPD
models. Taken together, these data suggest that restoring
MIF activity within the lung to “just the right amount” is
beneficial to the development of normal alveolar
architecture.
These data suggest that the mechanism of hyperoxia-
induced BPD in the murine model may be similar to
lack of MIF. This notion is made further plausible by re-
cent observations that MIF expression is strongly
governed by the activation of hypoxia-inducible factor
1α (HIF-1α) [34,35]. Lack of HIF has been associatedwith animal models of BPD [36,37], and this observation
provides a potential mechanistic link. Furthermore,
increased Ang2 has been associated with decreased HIF-
1.alpha; [38]. This notion underscores prior observations
that both a lack and an excess of angiogenesis during a
critical stage of pulmonary development disrupts
alveolarization [14,39-41]. While a considerable amount
of data has been published on the lack of vascular devel-
opment as a hallmark of BPD [39,42], we posit that an
excess of pro-angiogenic factors [14,17,19,40,42] during
the critical stage of lung development also lead to the
same end result. We suggest that further investigations
into the role of decreased MIF activity leading to
decreased HIF-1α action, and the association with
increased Ang2-decreased Ang1-Tie2 signaling pathway,
would be fruitful in understanding the pathogenesis of
BPD. Since the functioning of these molecules are
context-dependent, studies need to be pursued in
developmentally-appropriate pulmonary models.
Recently, the MIF −173*C allele, which predisposes to
higher MIF production, was associated with a decreased
incidence of BPD, independently from mechanical venti-
lation and oxygen exposure [4]. Conceivably, use of
small molecule MIF modulators as a therapeutic ap-
proach to prevent BPD may be guided by a patient’s gen-
etic predisposition based on MIF alleles.
Conclusions
In summary, we noted that a lack or excess of MIF in
the developing lung both lead to an alveolar simplifica-
tion pulmonary phenotype, which was not further
worsened by hyperoxia exposure in the survivors. These
effects were associated with alterations in the protein ex-
pression of the Ang1, Ang2 and Tie2 angiogenic factors.
Use of a MIF agonist in the WT-BPD or MIF antagonist
in the MIFTG-BPD models restored the pulmonary
phenotype towards normalcy. We speculate that the
Ang1-Ang2-Tie2 axis signaling pathway mediates the
pulmonary effects of MIF in the developing lung.
The present findings have clinical relevance and support
our earlier work showing lower MIF tracheal aspirate
levels in human infants developing BPD [2]. We speculate
that restoring or enhancing MIF activity in the developing
lung, without reaching supra-physiological levels, has the
potential to improve impaired alveolarization in the
infants at risk for BPD. Additional research is needed to
ascertain the ideal circumstances for augmenting MIF ac-
tion in the lung, potentially via the systemic or intra-
pulmonary application of small molecule MIF modulators
that would be protective of the developing lung
predisposed to BPD.
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